Does Rallies show Form 4 insider transactions for LPCN?

Yes. Rallies tracks LPCN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is LPCN research on Rallies investment advice?

No. Rallies provides research, data, and educational context for LPCN. It does not provide personalized investment advice.

LPCN (Lipocine Inc.) Stock Analysis - Insider Trades

Lipocine Inc. (LPCN) is a publicly traded Healthcare sector company. As of May 21, 2026, LPCN trades at $2.24 with a market cap of $18.22M and a P/E ratio of 0.00. LPCN moved +2.27% today. Year to date, LPCN is -69.32%; over the trailing twelve months it is -38.46%. Its 52-week range spans $1.81 to $12.37. Analyst consensus is buy with an average price target of $6.00. Rallies surfaces LPCN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading LPCN stock inside the company?

Recent LPCN insider activity includes Higuchi John W. bought 40.00K, Higuchi John W. bought 123.00K, Patel Mahesh V. bought 25.00K, Patel Mahesh V. bought 25.00K, and Patel Mahesh V. bought 8.71K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

LPCN Key Metrics

Key financial metrics for LPCN
Metric	Value
Price	$2.24
Market Cap	$18.22M
P/E Ratio	0.00
EPS	$0.00
Dividend Yield	0.00%
52-Week High	$12.37
52-Week Low	$1.81
Volume	35
Avg Volume	0
Revenue (TTM)	$2.00M
Net Income	$-11.43M
Gross Margin	0.00%

Recent LPCN Insider Trades

Higuchi John W. bought 40.00K (~$81.20K) on Apr 7, 2026.
Higuchi John W. bought 123.00K (~$252.15K) on Apr 6, 2026.
Patel Mahesh V. bought 25.00K (~$50.75K) on Apr 6, 2026.
Patel Mahesh V. bought 25.00K (~$50.50K) on Apr 2, 2026.
Patel Mahesh V. bought 8.71K (~$43.79K) on May 25, 2023.

Latest LPCN News

Lipocine Phase 3 PPD Trial Fails; Q1 Net Loss of $0.52/Share — May 7, 2026
Lipocine’s Oral Brexanolone Fails Phase 3 Endpoint, Shows −7.2 HAM-D Gains — Apr 2, 2026
Lipocine Reports $9.6M 2025 Loss, $14.9M Cash, April LPCN 1154 Data — Mar 10, 2026

LPCN Analyst Consensus

2 analysts cover LPCN: 0 strong buy, 1 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.00.

Common questions about LPCN

Who is trading LPCN stock inside the company?: Recent LPCN insider activity includes Higuchi John W. bought 40.00K, Higuchi John W. bought 123.00K, Patel Mahesh V. bought 25.00K, Patel Mahesh V. bought 25.00K, and Patel Mahesh V. bought 8.71K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for LPCN?: Yes. Rallies tracks LPCN insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is LPCN research on Rallies investment advice?: No. Rallies provides research, data, and educational context for LPCN. It does not provide personalized investment advice.